Today were published SPDR S&P Biotech (ETF) (NYSEARCA:XBI)‘s daily net flows. The ETF registered $327.64M asset inflows for 11.66% increase, reaching $3138.32M after yestarday’s trading session. The chart of SPDR S&P Biotech (ETF) shows positive short-term setup. In the net flows calculation is not included the performance of the etf but only share redemptions (outflows) and share purchases (inflows). Net inflows create excess cash for managers to invest, which theoretically creates demand for the etf’s holdings. The ETF increased 0.64% or $0.42 on November 11, hitting $66.21. SPDR S&P Biotech (ETF) (NYSEARCA:XBI) has risen 20.40% since April 12, 2016 and is uptrending. It has outperformed by 15.42% the S&P500.
The ETF’s YTD performance is -19.81%, the 1 year is -15.34% and the 3 year is 13.06%.
The ETF’s average P/E ratio is 19.64, the price to book is 2.76, the price to sales is 7.08 and the price to cashflow is 10.94. SPDR S&P Biotech (ETF) is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001. The fund’s top holdings are: Sarepta Therapeutics Inc. for 3.86% of assets, TESARO Inc. for 3.53%, Incyte Corporation for 2.94%, Alexion Pharmaceuticals Inc. for 2.80%, United Therapeutics Corporation for 2.68%, Celgene Corporation for 2.62%, Gilead Sciences Inc. for 2.53%, Biogen Inc. for 2.53%, Regeneron Pharmaceuticals Inc. for 2.40%, Ionis Pharmaceuticals Inc. for 2.40%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0% yield.
More notable recent SPDR S&P Biotech (ETF) (NYSEARCA:XBI) news were published by: Investorplace.com which released: “Buy the SPDR S&P Biotech (ETF) (XBI) TODAY â€“ Here’s Why” on November 09, 2016, also Bloomberg.com with their article: “Options Insight: How to Trade the SPDR S&P Biotech ETF” published on October 06, 2016, Benzinga.com published: “Scott Bauer’s SPDR S&P Biotech ETF Trade” on October 07, 2016. More interesting news about SPDR S&P Biotech (ETF) (NYSEARCA:XBI) were released by: Investorplace.com and their article: “SPDR S&P Biotech (ETF) (XBI): Embrace the Biotech Bulls’ Return” published on August 11, 2016 as well as Nasdaq.com‘s news article titled: “SPDR S&P Biotech Breaks Above 200-Day Moving Average – Bullish for XBI” with publication date: July 20, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.